Dr Mark Cutler, Associate Director, Pfizer Vaccine Research, joined us at the World Vaccine Cell Culture Congress in Washington in 2012 to present on strategies to develop a stable packaging cell line and process, leading to the successful generation and identification of stable Vero-G cell lines. Testing and characterization of cell lines is intrinsic to this development process and takes place in three stages: Cell line characterization, Safety and End of production testing.
In summary, this presentation discusses the successful generation and identification of stable Vero-G cell lines, a cell line that exhibited stable G expression over multiple serial passaging in culture. The cell culture and virus production processes are adaptable to serum free medium and scalable to manufacturing target titers in bench top bioreactor.
Why not download the full presentation and find out more about strategies to develop a stable packaging cell line and process, then tell us what you think below:
- Delivering the efficient propagation of VSV vectors defective for G expression by producing a stable packaging cell line: Vero-G
- How high titers were achieved in adherent monolayers and also suspension culture, and in small bioreactors on mirco-carriers
- Strategies for adapting processes to serum-free medium; from cell culture, infection and virus production.